Treatments targeting amyloid protein provide ‘no clinical benefit’ and only cause brain swelling and bleeding, new research finds

The review said a certain class of drugs had little clinical benefit, but many Alzheimer’s experts criticized the analysis, saying it unfairly lumped failed drugs with two recently approved treatments.

Goetz is the creator of “Drug Story,” a new podcast about the disease business. Biologically, how the GLP-1 is delivered into the body should make little difference: It’s the same peptide, just in a different formulation. But in our human reality, it ...

For more than a decade, a class of drugs called BET inhibitors has been tested in cancer trials with high expectations. The biology looked promising. Many cancers depend on oncogenes that "Bromo- and Extra-Terminal domain" (BET) proteins help activate,